The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | The emerging role of ctDNA in liver cancer management
David Pinato, MD, PhD, Imperial College London, London, UK, discusses the potential of circulating tumor DNA (ctDNA) as a biomarker for diagnosing and monitoring hepatocellular carcinoma (HCC). Tumor-released variants in ctDNA can provide information on disease activity. In HCC, ctDNA can help identify patients who may be curable and have a lower risk of relapse. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
